SCIBAC has developed a patented MERGE (Microbial Enhanced Recombinants Generated by Evolution) platform for strain improvement works by harnessing and directing a natural evolutionary process where different species can mate.
Jeanette Mucha, CEO, Chief Science Officer and Co-Founder of SCIBAC, gave this illuminating overview of how they design live biotherapeutics to target antibiotic resistant disease in the microbiome, how MERGE works, strain improvements, their investment needs and more, at ABLC Global 2018 in San Francisco
Category: 8-Slide Guide